Medipath becomes a global AI-powerhouse with the
deployment of Ibex solutions across 30 laboratories in
France
TEL
AVIV, Israel, and FREJUS, France, Sept. 2,
2022 /PRNewswire/ -- Ibex Medical Analytics, the
leader in AI-powered cancer diagnostics, and Medipath, the largest
network of private pathology labs in France, today announced a new agreement to
expand the deployment of Artificial Intelligence (AI) to additional
labs in the Medipath network. The deployment includes new
AI-powered tools for diagnosing multiple tissue types and will
support Medipath pathologists with improved diagnostic accuracy and
efficiency.
Medipath, which provides pathology services to more than 250
hospitals and clinics across France, is a network of 115 pathologists and
more than 580 employees, spread across 30 sites.
France, as with most European
countries, is challenged by an increasing prevalence of cancer and
a decline in the number of pathologists. Coupled with rapid
advances in personalized medicine over the last several years that
have resulted in a growing complexity of cancer diagnosis, these
trends have led to increased demand for diagnostic testing and
growing workloads imposed on pathology departments. Pathologists
play a crucial role in the detection and diagnosis of cancer, with
their assessments being vital for reaching correct treatment
decisions by oncologists and improving patient survival rates.
Clearly, there is a growing need for automated solutions and
decision-support tools that help pathologists detect cancer to the
utmost accuracy more rapidly.
The Galen™ suite of solutions from Ibex supports pathologists in
a variety of tasks during the diagnosis of breast, prostate, and
gastric biopsies and helps improve the accuracy of cancer
diagnosis, reduce turnaround time, boost productivity and improve
user experience for pathologists. It is the most widely deployed AI
technology in pathology and used as part of everyday clinical
practice at laboratories, hospitals and health systems worldwide.
Galen demonstrated outstanding outcomes across multiple clinical
studies performed on various tissue types and diagnostic
workflows1,2,3,4,5.
Since 2020, pathologists at Medipath have been using Ibex's
solutions in routine clinical practice, paving the way to an
overall digitization of their pathology services using Philips'
IntelliSite Pathology Solution which included deployment of a
network of high-throughput digital pathology scanners across 15
sites, connected via the Philips Image Management Solution.
Under the new expansion agreement, Medipath will rollout Ibex's
solutions to all sites in France.
Pathologists at Medipath will use the Galen platform for decision
support during primary diagnosis of breast, prostate and gastric
biopsies, enabling them to improve diagnostic accuracy and
streamline workflows via automated case prioritization, AI-powered
cancer detection, reporting, pre-ordering of immunohistochemistry
(IHC) and other ancillary tests and other productivity-enhancing
tools. This unprecedented scale of AI implementation at the network
level has the potential to provide Medipath with economies of scale
and efficiency gains, reduced operational costs and improved
service levels.
"We are writing a new chapter on our digital transformation
journey, and excited to work with our partners at Ibex on this
expansion project, making their AI portfolio available to more labs
and pathologists in our network," said Dr. Olivier Vire, Chairman of the Medipath group.
"Integrating Ibex as a foundation of primary diagnosis helps our
pathologists improve the accuracy of reporting and optimize
processes in our labs that ultimately deliver better patient care.
We look forward to introducing additional AI tools from Ibex across
our network as Medipath remains committed to being the leading
AI-enabled healthcare provider in France".
"Medipath are trailblazers! We're working closely with their
team to roll out an expansive AI-powered digital pathology
network," said Stuart Shand, Chief
Commercial Officer at Ibex Medical Analytics. "Ibex is committed to
providing every patient with a precise, timely and personalized
cancer diagnosis, made possible with our AI technology that
supports real-world needs from physicians."
Ibex Medical Analytics presents at the European Congress of
Pathology which takes place in Basel,
Switzerland, between September
3-7 (booth no. 1).
About Ibex Medical Analytics
Ibex pioneers AI-powered cancer diagnostics in pathology. We
empower physicians to provide every patient with an accurate,
timely and personalized cancer diagnosis by developing
clinical-grade AI algorithms and digital workflows that help detect
and grade cancer in biopsies. Our Galen™ platform is the first-ever
AI-powered integrated diagnostics solution in pathology and used in
routine clinical practice worldwide, supporting pathologists and
providers in improving the quality and accuracy of diagnosis,
implementing comprehensive quality control, reducing turnaround
times and boosting productivity with more efficient workflows.
Ibex's Artificial Intelligence technology is built on Deep Learning
algorithms trained by a team of pathologists, data scientists and
software engineers. For more information, go to
www.ibex-ai.com.
About Medipath
For more than 20 years, Medipath brings together independent
pathologists, active in screening and medical diagnosis in
anatomical pathology and cytology. The company has more than 115
associate physicians (including 10 referring pathologists in the
national networks of expertise for rare pathologies of the National
Cancer Institute and 10 molecular pathologists) and more than 580
employees, spread over 30 geographical sites, which today gives it
a prominent position in the pathology market. Led by physicians,
the company pursues a public health mission in the screening and
diagnosis of cancer, collaborates with more than 250 healthcare
establishments and processes more than 1.5 million cases each year,
including 140,000 diagnoses of cancer. Medipath is a pioneer in its
quality approach in the accreditation of its technical platforms
and medical-administrative sites. Its "general" and molecular
pathology platforms are accredited to perform the molecular tests
necessary for targeted therapies (PCR and Next generation
sequencing). The excellence of its technical platforms and its
geographical coverage allow Medipath to successfully pursue its
primary objective: "a pooling for access to excellence, a local
expertise in patient care".
Media Contacts
Ibex
Nechama
Feuerstein
FINN Partners
Nechama.feuerstein@finnpartners.com
+1-551-444-0784
Medipath Media Contacts
Mathilde Lise
Attila Agency
m.lise@attila.agency
[1] Pantanowitz et al., An artificial intelligence algorithm for
prostate cancer diagnosis in whole slide images of core needle
biopsies: a blinded clinical validation and deployment study, THE
LANCET Digital Health Aug 2020
[2] Vincent-Salomon et al., A Multi-Feature AI-Based Solution
for Cancer Diagnosis in Breast Biopsies: A Prospective
Blinded Multi-Site Clinical Study, European Congress of Pathology
2021
[3] Comperat et al., Clinical Level AI-Based Solution for Primary
Diagnosis and Reporting of Prostate Biopsies in Routine Use: A
Prospective Reader Study, European Congress of Pathology 2021
[4] Raoux et al., Novel AI-Based Solution for Supporting Primary
Diagnosis of Prostate Cancer Increases the Accuracy and Efficiency
of Reporting in Clinical Routine, USCAP 2021
[5] Sandbank et al., Validation and Clinical Deployment of an
AI-Based Solution for Detection of Gastric Adenocarcinoma and
Helicobacter pylori in Gastric Biopsies, USCAP 2022
Logo -
https://mma.prnewswire.com/media/1839936/Ibex_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ibex-and-medipath-sign-multi-year-multi-site-and-multi-tissue-expansion-of-ai-for-cancer-diagnosis-across-france-301617037.html
SOURCE Ibex Medical Analytics